MedTrace Logo

Infusion of Autologous T Regulatory Cells (T Reg) at the Time of Transplantation of Allogenic Islets of Langerhans

NCT04820270 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-03-29

No results posted yet for this study

Summary

Open single armed study to investigate safety and feasibility of administrating autologous T regulatory cells at the time of allogenic islet transplantation.

Conditions

  • Type1diabetes

Interventions

OTHER

Autologous T regulatory cells

Enriched autologous T regulatory cells are given back to the patient at the time of islet transplantation

Sponsors & Collaborators

  • The Nordic Network For Clinical Islet Transplantation

    lead OTHER

Principal Investigators

  • Torbjörn Lundgren, MD · Karolinska University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2021-04-30
Completion
2021-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04820270 on ClinicalTrials.gov